MaxCyte : Purchase of Common Stock

MaxCyte, Inc.

("MaxCyte" or the "Company")

Purchase of Common Stock - PDMR dealing

Gaithersburg, Maryland, November 23, 2021 -MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announces that Richard Douglas, Non-Executive Chairman of MaxCyte, Inc. purchased 20,000 shares on the open market of common stock of the Company ("Common Stock"). The 20,000 shares of Common Stock were purchased at an average price of $11.124 per share ("Purchase"). The Purchase represents approximately 13% of Richard Douglas' aggregate equity and option holdings in the Company's stock capital.

Following the Purchase, Richard Douglas holds 20,000 shares of Common Stock representing 0.02% of the issued stock capital of the Company. Following the Purchase, Richard Douglas holds a further 131,600 options over Common Stock.

The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 100,838,137 and the number of restricted shares of Common Stock trading under the symbol 'MXCL' is 330,000.

MaxCyte Contacts:

US IR Adviser Gilmartin Group David Deuchler, CFA	[phone] [e-mail]
Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden	[phone]
UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh	[phone] [e-mail]

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx™, STx™ and GTx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and/or persons closely associated with them:

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	a) Richard Douglas
2	Reason for the notification
a)	Position/status	a) Non-Executive Chairman
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	MaxCyte, Inc.
b)	LEI	54930053YHXULRFCU991
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	$0.01 ordinary shares US57777K1060
b)	Nature of the transaction	Purchase of Common Stock
c)	Price(s) and volume(s)	Price(s) per Ordinary Share Volume(s) a) $11.005 b) $11.01 c) $11.03 d) $11.04 e) $11.05 f) $11.06 g) $11.08 h) $11.09 i) $11.1 j) $11.11 k) $11.12 l) $11.13 m) $11.139 n) $11.14 o) $11.15 p) $11.159 a) 100 b) 697 c) 360 d) 512 e) 128 f) 64 g) 200 h) 528 i) 300 j) 300 k) 2,400 l) 3,200 m) 1,400 n) 7,000 o) 2,300 p) 511
d)	Aggregated information: · Aggregated volume: · Price:	20,000 N/A
e)	Date of the transaction	22 November 2021
f)	Place of the transaction	Nasdaq Stock Market